Google Inc vs Novartis AG — how do they compare? Google Inc trades at $344.91 (market cap $4.20T), while Novartis AG trades at $152.38 (market cap $295.37B). The key difference: Google Inc is far larger — about 14.2× Novartis AG's market cap, and Novartis AG pays the higher dividend (3.07%). Which is the better fit depends on your goals.
| GOOG | NVS | |
|---|---|---|
Market Cap | $4.20T | $295.37B |
Volume | 1,511,127 | — |
Sector | Technology | Health |
52-Week High | $399.06 | $168.62 |
52-Week Low | $200.19 | $119.31 |
Enterprise Value | $4.09T | $336.69B |
Dividend Yield | 0.26% | 3.07% |
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOG) trades at $355.84, up 0.67% on the day, with a bullish technical signal from moving averages and strong quarterly earnings beats. The company reported robust revenue growth to $402.84 billion in 2025, with net income surging to $132.17 billion, and announced a new AI leadership structure to accelerate Gemini development amid rising user adoption.
Outlook remains positive with an 86.84% analyst buy rating and a $431.67 consensus price target, though risks include high capital expenditure for AI infrastructure and regulatory scrutiny. The stock offers growth potential from AI monetization but faces volatility from tech sector pressures and antitrust investigations.
Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.
The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.
Trailing returns across standard periods
Latest headlines on both assets
Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →